Duvelisib (chronic lymphatic leukemia (CLL), after ≥ 2 prior therapies)

Subject:

• Active Substance: Duvelisib
• Name: Copiktra^®
• Therapeutic area: Chronic lymphatic leukemia
• Pharmaceutical company: Secura Bio Limited

Time table:

• Start: 01.02.2022
• Final decision by G-BA: 21.07.2022

Final decision:

• Patients who have not yet received a BTK inhibitor and/or BCL2 inhibitor:
  • No additional beneft proved
• After prior therapy with at least one BTK inhibitor:
  • No additional benefit proved
• After prior therapy with at least one BCL2 inhibitor:
  • No additional benefit proved
• After prior therapy with at least one BTK inhibitor and one BCL2 inhibitor:
  • No additional benefit proved